Lead Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Collaborators

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•Meet the 2006 Wingerchuk diagnostic criteria;
•NMO-immunoglobulin G seropositive;
•Between 18 to 65 years old;
•Relapse: more than 2 relapses in recent 2 years; more than 1 relapses in recent 1 years;
•Expanded disability status scale: expanded disability status scale≤7.0, and visual acuity ≥20 / 100 at least in one eye
•Understand the purpose and procedures of this study, and written informed consent is obtained.

•Using immunosuppressive agents and other drugs affect evaluation, and drug withdrawal less than 3 months;
•Patients with any of the following diseases: transaminases elevation exceed 2 times of the normal upper limit; white blood cell \<4 × 109 / L, Hemoglobin \<80g / L, platelet \<100 × 109 / L;
•With serious cardiovascular, liver, kidneys and other vital organs and blood, endocrine system diseases, cancer history;
•With immunodeficiency, uncontrolled infection and active gastrointestinal diseases (such as gastric ulcer, etc.);
•Pregnancy, breast-feeding women and male or female who plans to conceive recently;
•Allergy to mycophenolate mofetil and prednisone.

Related studies

NCT05937750 · Long Term Efficacy and Safety

NCT06568549 · Kidney Transplantation, Mycophenolate Mofetil

NCT07256522 · Trigger Finger, Splint Therapy, and more

NCT06620809 · Neuromyelitis Optica Spectrum Disorders

NCT07202494 · Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and more

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients